Page last updated: 2024-08-26

cp-55,940 and CB-13

cp-55,940 has been researched along with CB-13 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bevan, SJ; Brain, CT; Coote, PR; Culshaw, AJ; Davis, AJ; Dziadulewicz, EK; Edwards, LJ; Fisher, AJ; Fox, AJ; Gentry, C; Groarke, A; Hart, TW; Huber, W; James, IF; Kesingland, A; La Vecchia, L; Loong, Y; Lyothier, I; McNair, K; O'Farrell, C; Peacock, M; Portmann, R; Schopfer, U; Yaqoob, M; Zadrobilek, J	1

Other Studies

1 other study(ies) available for cp-55,940 and CB-13

Article	Year
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. Journal of medicinal chemistry, 2007, Aug-09, Volume: 50, Issue:16 Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Brain; Cricetinae; Cricetulus; Cyclic AMP; Humans; Hyperalgesia; In Vitro Techniques; Microsomes, Liver; Naphthalenes; Radioligand Assay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship	2007

Article

Year

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.

Journal of medicinal chemistry, 2007, Aug-09, Volume: 50, Issue:16

Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Brain; Cricetinae; Cricetulus; Cyclic AMP; Humans; Hyperalgesia; In Vitro Techniques; Microsomes, Liver; Naphthalenes; Radioligand Assay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship

2007